Wave Life Sciences LTD Form 4 insider transactions

Kyle Moran, CFO of Wave Life Sciences Ltd., reports the sale of ordinary shares under a pre-arranged Rule 10b5-1 trading plan.

Wave Life Sciences CEO Paul Bolno sold 48,366 ordinary shares at an average price of $5.78 on August 21, 2024, under a pre-arranged Rule 10b5-1 trading plan.

RA Capital Management, along with related entities and individuals, reports changes in beneficial ownership of Wave Life Sciences Ltd. securities due to the grant of restricted share units and options to Dr. Peter Kolchinsky.

Director Adrian Rawcliffe reports acquisition of shares and options in Wave Life Sciences Ltd. as part of the 2024 Non-Employee Director Compensation Policy.

Director Aik Na Tan acquired shares and options in Wave Life Sciences Ltd. under the 2024 Non-Employee Director Compensation Policy.

Director Christian Henry reports acquisition of Wave Life Sciences shares and options as part of non-employee director compensation.

Director Mark Corrigan of Wave Life Sciences Ltd. reports the acquisition of stock options and restricted share units (RSUs) as part of the 2024 Non-Employee Director Compensation Policy.

Director Gregory L. Verdine reports acquisition of Wave Life Sciences shares and options as part of the 2024 Non-Employee Director Compensation Policy.

Director Heidi Wagner reports acquisition of Wave Life Sciences shares and options related to the 2024 Non-Employee Director Compensation Policy.

Director Ken Takanashi reports acquiring 16,115 ordinary shares and 32,230 share options in Wave Life Sciences Ltd.

Chandra Vargeese, Chief Technology Officer of Wave Life Sciences, exercised share options and acquired ordinary shares in a recent transaction.

Kyle Moran, CFO of Wave Life Sciences Ltd., reports the sale of 15,630 ordinary shares at an average price of $6.169 per share.